ArticleBMC cancer2024
In-depth analysis and trends of cancer mortality in Kazakhstan: a joinpoint analysis of nationwide healthcare data 2014-2022.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cross-Cultural Adaptation and Psychometric Validation of the Cancer Survivors' Unmet Needs Measure (CaSUN) in Russian- and Kazakh-Speaking Cancer Survivors in Kazakhstan.Healthcare (Basel, Switzerland) · 2026Article
- Global burden and trends of tracheal, bronchus, and lung cancer in adolescents and young adults: a secondary analysis of the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Machine Learning-Derived Risk Groups and Clinical Implementation of Survival Prediction in Lung Cancer: Evidence from a Kazakh National Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- A decade of esophageal cancer in Kazakhstan: what the national cancer registry reveals (2014-2023).Frontiers in oncology · 2026Article
- Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial.JMIR research protocols · 2025Article
- Article
- Article
- Mortality trends in Kazakhstan: insights from a million of deaths from 2014 to 2022.BMC public health · 2025Article
- The Burden and Trends of Gynecological Cancers in Asia from 1980 to 2021, with Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021.Current oncology (Toronto, Ont.) · 2025Article
- Survival disparities and predictors in gastric cancer: a population-based study from Kazakhstan (2012-2023).Frontiers in oncology · 2025Article
- Article
- Epidemiology of liver cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2023.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer remains a leading cause of death both globally and in Kazakhstan, making it crucial to track its mortality trends. This study aimed to investigate cancer mortality trends from 2014 to 2022 in Kazakhstan.
methodsThis study utilized data from Kazakhstan's Unified National Electronic Health System to perform descriptive data analysis and employed Joinpoint regression models to analyze average annual percent change (AAPC) in cancer-related mortality estimates. The authors also examined the mortality-to-incidence ratio (MIR) and proportionate mortality (PM).
resultsThe study analyzed 123,622 cancer-related death reports from 2014 to 2022. Major causes included trachea, bronchus, and lung cancer (16.01%), stomach cancer (11.43%), and colon and rectum cancer (10.05%), accounting for 37.48% of all cancer-related deaths. AAPCs showed a significant increase in mortality for individuals aged 18-44 (1.36%; 95% CI: 0.05%; 2.71%), while those aged 45-59 and 60-74 experienced decreases of -2.02% (95% CI: -3.05%; -0.96%) and - 2.10% (95% CI:-3.22%; -0.96%), respectively. PM was stable until 2019 but decreased from 2020 to 2021, while MIR increased during the same period. A significant decrease in oesophageal cancer mortality was observed in both females (-4.03%; 95% CI: -6.11%; -1.83%) and males (-2.44%; 95% CI: -4.89%; -0.02%), whereas ovarian cancer mortality increased by 0.95% (95% CI: 0.03%; 1.91%). In males, mortality from trachea, bronchus, and lung cancers decreased by -2.14% (95% CI: -3.00%; -1.25%), while "other neoplasms" rose by 6.21% (95% CI: 1.40%; 11.27%). Regional analysis highlighted variability, with the Kyzylorda region showing a pronounced increase in mortality (27.18%; 95% CI: 14.11%; 42.35%).
conclusionsDespite slight increases in MIR during the COVID-19 pandemic, overall cancer mortality trends remained stable. The findings highlight the need for targeted interventions, especially for individuals aged 18-44, ovarian cancer, and "other neoplasms". Further research is needed to explore regional mortality variations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.